Alpha Tau Medical (DRTS) to Release Quarterly Earnings on Wednesday

Alpha Tau Medical (NASDAQ:DRTS) is expected to be posting its Q4 2025 results before the market opens on Wednesday, March 11th. Analysts expect the company to announce earnings of ($0.13) per share for the quarter. Interested persons are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Friday, March 20, 2026 at 5:00 PM ET.

Alpha Tau Medical Stock Up 4.7%

Shares of NASDAQ DRTS opened at $6.71 on Tuesday. The stock’s 50-day simple moving average is $6.94 and its two-hundred day simple moving average is $5.07. Alpha Tau Medical has a twelve month low of $2.30 and a twelve month high of $8.60. The firm has a market capitalization of $569.14 million, a P/E ratio of -12.90 and a beta of 1.02.

Hedge Funds Weigh In On Alpha Tau Medical

A number of large investors have recently modified their holdings of DRTS. Envestnet Asset Management Inc. purchased a new stake in Alpha Tau Medical in the third quarter worth approximately $62,000. Bank of America Corp DE raised its stake in shares of Alpha Tau Medical by 2,779.1% during the third quarter. Bank of America Corp DE now owns 22,457 shares of the company’s stock worth $101,000 after acquiring an additional 21,677 shares in the last quarter. Wells Fargo & Company MN raised its stake in shares of Alpha Tau Medical by 291.7% during the fourth quarter. Wells Fargo & Company MN now owns 23,500 shares of the company’s stock worth $116,000 after acquiring an additional 17,500 shares in the last quarter. Millennium Management LLC bought a new stake in shares of Alpha Tau Medical in the 3rd quarter worth approximately $170,000. Finally, Mariner LLC lifted its holdings in shares of Alpha Tau Medical by 185.8% in the 3rd quarter. Mariner LLC now owns 123,250 shares of the company’s stock worth $556,000 after acquiring an additional 80,129 shares during the last quarter. 2.65% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms recently weighed in on DRTS. Zacks Research upgraded shares of Alpha Tau Medical from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 17th. Piper Sandler reiterated a “neutral” rating and set a $5.00 target price on shares of Alpha Tau Medical in a research report on Wednesday, March 4th. Citigroup cut their price target on shares of Alpha Tau Medical from $8.00 to $7.00 and set a “buy” rating for the company in a research note on Wednesday, December 10th. HC Wainwright reissued a “buy” rating on shares of Alpha Tau Medical in a report on Wednesday, December 10th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Alpha Tau Medical in a research report on Wednesday, January 21st. Two equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Alpha Tau Medical presently has a consensus rating of “Hold” and an average price target of $7.00.

About Alpha Tau Medical

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.